Patients who relapse within 6 months after completion of therapy are thought to be “platinum-resistant"(Pt-R) and felt to have a worse prognosis. Currently, Single agent such as topotecan, liposomal doxorubicin, vinorelbine, docetaxel and gemcitabine is used as second line setting for patients with Pt-R ovarian cancer. But, some articles have been reported that patients who have Pt-R ovarian cancer may still benefit from re-treatment with platinum compounds after an interval of treatment with nonplatinum agents. The purpose of our study was to review our experience with subsequent platinum based re-treatment in women with Pt-R ovarian cancer. We studied seven patients who had relapsed within six months of their recent exposure to platinum. They were treated with platinum based combination with topotecan, irinotecan, or docetaxel. The median age was 52 years, six patients was received paclitaxel and carboplatin combination chemotherapy prior to re treatment with platinum compounds. They received a median number of six cycles as first line chemotherapy. Two patients achieved complete respons (CR) and 5 had stable disease(SD). The median time to progression(TTP) of 1st line treatment was 8.5 months (95% CI 7.8-9.3) and the median platinum free interval was 4.6 months. All of them had good performance status(ECOG 0) before 2nd line treatment. Four patients received docetaxel-carboplatin and 3 had topotecan/irinotecan-cisplatin combination regimen. A median number of 6 cycles as re treatment with platinum compounds was received. One patient achieved CR, one patient achieved partial response, while 5 patients achieved SD. The median TTP for these seven patients after re-treatment with platinum compounds was 7.3 months (95% CI 5.1-9.4). Four patients had progressive disease and received further salvage therapy with another regimen. The median overall survival from the time deemed to be Pt-R is 22.8 months (95% CI 18.8-26.8). Our small retrospective series suggest that the Pt-R category is still less clear. Patients who have been deemed Pt-R may still benefit from subsequent platinum based re-treatment.